ArticleThe Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics2022
Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV.
Article in The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Retrospective analysis of HIV pre-exposure prophylaxis (PrEP) awards under Executive Order 14168 on gender ideology in the U.S. 2012-2025.Public health in practice (Oxford, England) · 2026Article
- Cost-effectiveness of leveraging long-acting injectable cabotegravir to expand PrEP coverage among MSM in two contrasting North American cities.Journal of the International AIDS Society · 2026Article
- Exploration of implementation determinants and strategies for same-day oral PrEP in community-based organizations and federally qualified health centers.Implementation science communications · 2025Article
- Synergizing Digital and Physical Approaches: Experience Summary of the HIV PrEP Promotion Project.China CDC weekly · 2025Article
- Spatiotemporal Analysis of HIV/AIDS Incidence in China From 2009 to 2019 and Its Association With Socioeconomic Factors: Geospatial Study.JMIR public health and surveillance · 2024Article
- Evolving Challenges in the Implementation of China's "Four Frees and One Care" Policy for HIV/AIDS.Risk management and healthcare policy · 2024Article
- Estimating The Impact Of Out-Of-Pocket Cost Changes On Abandonment Of HIV Pre-Exposure Prophylaxis.Health affairs (Project Hope) · 2024Article
- INTRODUCTIONThe Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2022Article
- Three Drugs, Two Pills, One Algorithm: A Cross-Sectional Pilot Study of Consolidated Guidelines for HIV PrEP, PEP, and Treatment Initiation for Resource-Limited and Non-specialty Settings in the United States.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiretroviral pre-exposure prophylaxis (PrEP) is protective against HIV. Low utilization rates amongst HIV vulnerable populations are due in part to the high cost of PrEP. Generic PrEP offers the potential to improve health at significantly reduced costs. In this study, we examine early utilization patterns and prices for generic PrEP. We discuss the opportunities and challenges for generic PrEP to improve health among HIV vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.